Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Agustín Sancho-SaldañaAnna Gil SánchezBibiana Quirant-SanchezLara NoguerasSilvia PeraltaMaria José SolanaCristina González-MingotYhovanni GallegoLaura QuibusCristina Ramo-TelloSilvia Presas-RodríguezEva Martínez-CáceresPascual TorresJosé Vicente HervásJoan VallsLuis BrievaPublished in: Journal of clinical medicine (2022)
According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.